Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Head & Neck 5Endocrine 5

Conditions

Neuroendocrine Tumors 147Carcinoma, Neuroendocrine 57Thyroid Cancer, Papillary 54Pheochromocytoma 52Paraganglioma 42Thyroid Neoplasms 41Pituitary Neoplasms 40Neoplasms 32Adrenocortical Carcinoma 31Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 23Lung Neoplasms 22Small Cell Lung Carcinoma 21Sarcoma 20Carcinoid Tumor 20Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Pancreatic Neoplasms 16Colorectal Neoplasms 16Adrenal Gland Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Carcinoma, Renal Cell 15Adenocarcinoma, Follicular 15

Interventions

trametinib 1spartalizumab 1pembrolizumab 1lenvatinib 1gallium Ga 68 dotatate 1dabrafenib 1Sorafenib 1Sodium Iodide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Thyroid cancer, Hurthle cell × Endocrine × 1 year × Clear all
NCT00001160 2026-05-12

Studies on Tumors of the Thyroid

National Institutes of Health Clinical Center (CC)

Recruiting
2,500 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01398085 2026-05-07

IoN

University College, London

Phase 2/3 Active not recruiting
504 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
35 enrolled 14 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT02973997 2025-08-29

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Academic and Community Cancer Research United

Phase 2 Completed
57 enrolled 14 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡